Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes

Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes

BACKGROUND: ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) may have anti-tumor properties. We investigated whether the use of ACEI/ARBs affects the clinical outcomes of primary breast cancer patients receiving taxane and anthracycline-based neoadjuvant chemotherapy.

Bibliographic Details
Main Authors: Chae, Young Kwang, Brown, Erika N., Lei, Xiudong, Melhem-Bertrandt, Amal, Giordano, Sharon H., Litton, Jennifer K., Hortobagyi, Gabriel N., Gonzalez-Angulo, Ana M., Chavez-MacGregor, Mariana
Format: Online
Language:English
Published: Ivyspring International Publisher 2013
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3753529/
id pubmed-3753529
recordtype oai_dc
spelling pubmed-37535292013-08-27 Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes Chae, Young Kwang Brown, Erika N. Lei, Xiudong Melhem-Bertrandt, Amal Giordano, Sharon H. Litton, Jennifer K. Hortobagyi, Gabriel N. Gonzalez-Angulo, Ana M. Chavez-MacGregor, Mariana Research Paper BACKGROUND: ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) may have anti-tumor properties. We investigated whether the use of ACEI/ARBs affects the clinical outcomes of primary breast cancer patients receiving taxane and anthracycline-based neoadjuvant chemotherapy. Ivyspring International Publisher 2013-08-10 /pmc/articles/PMC3753529/ /pubmed/23983819 http://dx.doi.org/10.7150/jca.6888 Text en © Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Chae, Young Kwang
Brown, Erika N.
Lei, Xiudong
Melhem-Bertrandt, Amal
Giordano, Sharon H.
Litton, Jennifer K.
Hortobagyi, Gabriel N.
Gonzalez-Angulo, Ana M.
Chavez-MacGregor, Mariana
spellingShingle Chae, Young Kwang
Brown, Erika N.
Lei, Xiudong
Melhem-Bertrandt, Amal
Giordano, Sharon H.
Litton, Jennifer K.
Hortobagyi, Gabriel N.
Gonzalez-Angulo, Ana M.
Chavez-MacGregor, Mariana
Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes
author_facet Chae, Young Kwang
Brown, Erika N.
Lei, Xiudong
Melhem-Bertrandt, Amal
Giordano, Sharon H.
Litton, Jennifer K.
Hortobagyi, Gabriel N.
Gonzalez-Angulo, Ana M.
Chavez-MacGregor, Mariana
author_sort Chae, Young Kwang
title Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes
title_short Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes
title_full Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes
title_fullStr Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes
title_full_unstemmed Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes
title_sort use of ace inhibitors and angiotensin receptor blockers and primary breast cancer outcomes
description BACKGROUND: ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) may have anti-tumor properties. We investigated whether the use of ACEI/ARBs affects the clinical outcomes of primary breast cancer patients receiving taxane and anthracycline-based neoadjuvant chemotherapy.
publisher Ivyspring International Publisher
publishDate 2013
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3753529/
_version_ 1612006121199894528

Similar Items